Temsirolimus

替西罗莫司

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NameTemsirolimus
Drug Alias NameTemsirolimusum坦罗莫司坦西莫司特姆莫司特罗莫司 +[9] 
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Molecular Glue
Mechanisms of ActionmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsSkin MelanomaCNS Embryonal TumorSolid tumours +[65] 
Global Approved IndicationsCarcinoma, Renal Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2007/05/30
Country/TerritoryFormer Serbia and MontenegroCzechiaBelgium +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncMercator Medsystems IncPf Prism Cv +[4] 
Inactive CompaniesDana-Farber Cancer InstituteWyeth LlcRadboud University Medical Center +[17] 
Active IndicationsIschemiaPeripheral Arterial DiseaseCarcinoma, Renal Cell +[4] 
Inactive IndicationsSkin MelanomaCNS Embryonal TumorSolid tumours +[61] 

Other Information

ATC CodeL01EG01
Related LinksWikipediaDrugBankKEGG